These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31911716)

  • 41. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 42. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 44. The new drug war.
    Parloff R
    Fortune; 2004 Mar; 149(5):144-6, 148, 150 passim. PubMed ID: 15015428
    [No Abstract]   [Full Text] [Related]  

  • 45. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle?
    Reinke T
    Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 48. Cancer drug prices and the free-market forces.
    Kantarjian H; Zwelling L
    Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
    [No Abstract]   [Full Text] [Related]  

  • 49. The opportunity cost of capital: development of new pharmaceuticals.
    Chit A; Chit A; Papadimitropoulos M; Krahn M; Parker J; Grootendorst P
    Inquiry; 2015; 52():. PubMed ID: 25933615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 51. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM
    Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract]   [Full Text] [Related]  

  • 52. A three-step plan for antibiotics.
    Nature; 2014 May; 509(7502):533. PubMed ID: 24877183
    [No Abstract]   [Full Text] [Related]  

  • 53. Seizures of Canadian drugs rise as Congress, Customs spar.
    Carreyrou J
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501
    [No Abstract]   [Full Text] [Related]  

  • 54. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
    Roman A
    Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
    [No Abstract]   [Full Text] [Related]  

  • 55. Risks and benefits of importing prescription medications from lower-income countries.
    Dhalla IA; Detsky AS
    JAMA; 2008 Sep; 300(12):1453-5. PubMed ID: 18812537
    [No Abstract]   [Full Text] [Related]  

  • 56. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cheat sheet to navigate the complex maze of exclusivities in the United States.
    Peng B; Tomas MC
    Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
    [No Abstract]   [Full Text] [Related]  

  • 58. Do drug prices reflect development time and government investment?
    Keyhani S; Diener-West M; Powe N
    Med Care; 2005 Aug; 43(8):753-62. PubMed ID: 16034288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Competitiveness in follow-on drug R&D: a race or imitation?
    DiMasi JA; Faden LB
    Nat Rev Drug Discov; 2011 Jan; 10(1):23-7. PubMed ID: 21151030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.